Licence extension approved for Hycamtin

The licensed indications for Hycamtin (topotecan) have been extended to include the treatment of patients with relapsed small cell lung cancer for whom re-treatment with first-line therapies is not considered appropriate.

Approval for the licence extension was granted on the based of trials in patients with small cell lung cancer who had relapsed following first line therapy and for whom retreatment with intravenous chemotherapy was not considered appropriate. In these patients Hycamtin was shown to significantly improve median survival times.

Further information: Merck Pharmaceuticals, Harrier House, High Street, Yiewsley, West Drayton, Middlesex UB7 7QG. Tel: (01895) 452307.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases